Welcome to Chinese Journal of Clinical Pharmacology and Therapeutics,Today is Share:

Chinese Journal of Clinical Pharmacology and Therapeutics ›› 2021, Vol. 26 ›› Issue (4): 395-400.doi: 10.12092/j.issn.1009-2501.2021.04.006

Previous Articles     Next Articles

Two-stage estimation on adjustment for cross-over in oncology trials

YU Quanji, NI Senmiao, YANG Min, ZHONG Zihang, ZHOU Jiawei, CAI Lixin, BAI Jianling, YU Hao   

  1. Department of Biostatistics, School of Public Health, Nanjing Medical University, Nanjing 211166, Jiangsu,China
  • Received:2020-12-31 Revised:2021-03-11 Online:2021-04-26 Published:2021-05-11

Abstract: AIM: To investigate the application of two-stage estimation (TSE) on adjustment for treatment switch in oncology trials.  METHODS: The theory and implementation of TSE method was described, and was applied to adjust the data from a two-arm randomized controlled trial of anti-tumor drugs. The changes of survival curves and hazard ratio of two groups after adjustment for cross-over were evaluated. In addition, the results of two-stage estimation and rank preserving structural failure time model (RPSFT) were compared. RESULTS: After adjustment for cross-over using TSE methods, the results showed that the median survival time of control group was shorter than the original one, and the hazard ratio was lower than the observed value. Moreover, TSE method showed similar results to rank preserving structural failure time model. CONCLUSION: The TSE method is relatively simple to use, reliable and has a good practice property in cross-over analysis of oncology trials. At the same time, it is necessary to pay attention to its application scopes. 

Key words: cross-over, two-stage estimation, accelerated failure time model

CLC Number: